Objective Evaluation of the dietary Na reduction trial in a community

Objective Evaluation of the dietary Na reduction trial in a community setting. 030) and 2875 mg/d ( 003) at 6-and 12-month follow-ups, respectively. In a sub-sample (urine volume of 1000 ml, baseline to 12 months), mean urinary Na excretion decreased from 3220 mg/d to 2875 mg/d ( 002). Conclusions Significant reductions in mean 24 h urinary Na were reported, but results fell short of the recommended guidelines of 1500 CCL2 mg/d for at-risk individuals. Our results reiterate the difficulty in implementing these guidelines in community-based programmes. More aggressive public health efforts, food industry support and health policy changes are needed to decrease Na levels in older adults to the recommended guidelines. tests were run using the SPSS statistical software package version 150 (SPSS Inc., Chicago, IL, USA) to assess differences in urinary Na at baseline and consecutive follow-ups. Results Baseline characteristics for participants are reported in Table 1. A total of 115 participants who met the established criteria for hypertension at baseline were randomized to the healthy lifestyle group (Group 2) and completed the 24 h urine collections. Average age was 751 (sd 53) years. Table 1 Baseline characteristics for persons with hypertension* in the lifestyle and nutrition intervention group (115): University of Pittsburgh Center for Healthy Aging, Key to Life Nutrition Program Desk 2 reviews 24 h urinary Na excretion in people with hypertension at baseline, six months and a year. At baseline, suggest urinary Na was 3128 mg/d (136 mmol/d). Evaluating baseline and 6-month follow-up exams (103 matched up pairs), the suggest urinary Na slipped to 2990 mg/d (130 mmol/d) on the 6-month follow-up. This 138 mg/d (6 mmol/d; 95 % CI C574, 810 mmol/d) decrease had not been statistically significant (= 030). When you compare baseline results using the 12-month follow-up (ninety matched up pairs), there is a 299 mg/d (13 mmol/d; 95 % CI 116, 2540 mmol/d) decrease in urinary Na excretion. This noticed reduce was significant (= 003). Mean urinary Na was decreased to 2875 mg/d (125 mmol/d). Desk 2 Urinary sodium excretion in people with hypertension in the approach to life and nutrition involvement group: College or university of Pittsburgh Middle for Healthy Maturing, Key alive Nutrition Program Desk 3 identifies the sub-sample of our hypertensive group, and compares seventy-seven people at baseline and 12-month follow-up who got a 24 h urine collection level of 1000 ml. The mean 63550-99-2 supplier urine quantity at baseline was 1956 ml weighed against 1985 ml on the 12-month follow-up go to. When you compare urinary Na excretion at baseline and 12-month follow-up utilizing a matched up paired check, mean urinary Na was 3220 mg/d (140 mmol/d) at baseline and reduced to 2875 mg/d (125 mmol/d) on the 12-month follow-up. This loss of 345 mg/d (15 mmol/d; 95 % CI 302, 2776 mmol/d) in urinary Na excretion was significant (= 002). Desk 3 Urinary sodium excretion within a sub-sample from the hypertensive group with 24 h urine quantity 1000 ml: College or university of Pittsburgh Middle for Healthy Maturing, Key alive Nutrition Program Dialogue In our demonstration programme changes in 24 h urinary Na excretion that occurred in persons with hypertension assigned to the Key to Life Nutrition Program intervention were significant, but fell short of the Institute of Medicine and the 2005 Dietary Guidelines recommendations (1500 mg Na/d) for this population. Our results reiterate how difficult it is to translate these recommended actions into community programmes. It is very unlikely that meeting Na reduction guidelines (i.e. 1500 mg/d) is usually obtainable, 63550-99-2 supplier especially among at-risk older individuals with hypertension(18). Numerous trials have demonstrated the beneficial effects and importance of reducing dietary Na to reduce blood pressure and ultimately heart disease and stroke(12C16). Past Na reduction trials (Table 4) have concluded that it is possible to use non-pharmacological approaches to reduce blood pressure and prevent hypertension in older adults. Table 4 Comparison of long-term sodium reduction trials The DASH trial results described above (average reductions in SBP and DBP of 6 mmHg and 3 mmHg, respectively; even greater when stratified for persons with stage 1 hypertension: average reductions in SBP and DBP of 11 mmHg and 6 mmHg, respectively(24)) sparked interest to investigate further how the DASH diet could be utilized 63550-99-2 supplier for blood pressure control and hypertension prevention, and led to the DASH-Sodium trial, a randomized controlled trial that assessed the effects of multiple Na levels on hypertensive adults. Mean age was 47 years for the DASH diet and 49 years for the control diet. Utilizing a crossover design participants received managed feedings with particular Na degrees of 3000, 2400 and 1500 mg/d for 30 d. Outcomes showed blood circulation pressure decrease at every one of the Na amounts, but the most reliable group was the DASH diet plan coupled with Na decrease to 1500 mg/d..